Additional file 1 of Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands ...
Additional file 1: Supplementary introduction: Table S1. Summary of previous studies on the cost-effectiveness PCV15, PCV20 and PCV21 in adults. Supplementary Methods: Figure S1. Schematic overview of the model. Figure S2. The annual incidence of IPD cases in the Netherlands among adults aged ≥60 years per 100,000 inhabitants over the period 2004-2019 by serotype category. Figure S3. Fitted vaccine effectiveness of PPV23 against vaccine-type IPD and vaccine-type hospitalized NIPP at time of vaccination, across different vaccination ages. Figure S4. Fitted vaccine efficacy of PCVs against vacci... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Journal contribution |
| Erscheinungsdatum: | 2024 |
| Verlag/Hrsg.: |
figshare
|
| Schlagwörter: | Medicine / Microbiology / FOS: Biological sciences / Pharmacology / Geology / FOS: Earth and related environmental sciences / Sociology / FOS: Sociology / Biological Sciences not elsewhere classified / Cancer / Science Policy / Infectious Diseases / FOS: Health sciences |
| Sprache: | unknown |
| Permalink: | https://search.fid-benelux.de/Record/base-29166312 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | https://dx.doi.org/10.6084/m9.figshare.25231181.v1 |
Additional file 1: Supplementary introduction: Table S1. Summary of previous studies on the cost-effectiveness PCV15, PCV20 and PCV21 in adults. Supplementary Methods: Figure S1. Schematic overview of the model. Figure S2. The annual incidence of IPD cases in the Netherlands among adults aged ≥60 years per 100,000 inhabitants over the period 2004-2019 by serotype category. Figure S3. Fitted vaccine effectiveness of PPV23 against vaccine-type IPD and vaccine-type hospitalized NIPP at time of vaccination, across different vaccination ages. Figure S4. Fitted vaccine efficacy of PCVs against vaccine-type IPD and vaccine-type hospitalized NIPP at time of vaccination, across different vaccination ages. Figure S5. The number of QALYs lost by age of death. Table S2. Epidemiological parameter values. Table S3. Serotype categories distinguished and serotype distribution from IPD cases aged 60+ years in the Netherlands in 2019. Table S4. Parameter values of costs. Table S5. Parameter values of quality-adjusted life ...